Does Cilostazol Interact with Cladribine?
CDI records a major classification for Cilostazol and Cladribine. The stored summary is: Potent BCRP, ENT1, and CNT3 transporter inhibitor may alter cladribine bioavailability, intracellular distribution, and renal elimination. The mechanism involves inhibition of bcrp, ent1, and cnt3 transporters. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Cilostazol Class
- Phosphodiesterase 3 Inhibitor
- Cladribine Class
- Purine Antimetabolite
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of BCRP, ENT1, and CNT3 transporters
What To Tell Your Doctor or Pharmacist
If you are taking Cilostazol and your doctor is considering prescribing Cladribine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider